Cover Image

HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: a cost-effectiveness analysis

The presence of human immunodeficiency virus (HIV) infection increases the risk of acquiring human papillomavirus (HPV) infection and developing HPV-related adversities. We aimed to estimate the cost-effectiveness of HPV vaccination for women living with HIV in a Chinese setting. A decision-analysis...

Full description

Saved in:
Bibliographic Details
Main Authors: Liu, Hanting (Author) , Zou, Maosheng (Author) , Shen, Mingwang (Author) , Kamarulzaman, Adeeba (Author) , Chen, Simiao (Author) , Li, Jinghua (Author) , Li, Rui (Author) , Liu, Huan (Author) , Zou, Zhuoru (Author) , Zhang, Lei (Author)
Format: Article (Journal)
Language:English
Published: 15 March 2025
In: International journal of cancer
Year: 2025, Volume: 156, Issue: 6, Pages: 1225-1235
ISSN:1097-0215
DOI:10.1002/ijc.35242
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/ijc.35242
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.35242
Get full text
Author Notes:Hanting Liu, Maosheng Zou, Mingwang Shen, Adeeba Kamarulzaman, Simiao Chen, Jinghua Li, Rui Li, Huan Liu, Zhuoru Zou, Lei Zhang
Description
Summary:The presence of human immunodeficiency virus (HIV) infection increases the risk of acquiring human papillomavirus (HPV) infection and developing HPV-related adversities. We aimed to estimate the cost-effectiveness of HPV vaccination for women living with HIV in a Chinese setting. A decision-analysis Markov model was developed to estimate the cost-effectiveness of 36 HPV vaccination strategies for women living with HIV aged 18-45 years, from the healthcare system perspective. With the status quo, not vaccinating women living with HIV would lead to 51.99% (51,985/100,000) HIV-related deaths; 35.10% (35,098/100,000) would develop genital warts, 0.36% (355/100,000) develop cervical cancer, and among which 63.66% (226/355) die from cervical cancer over their lifetime (1,601,457 person-years). With a willingness to pay (WTP) threshold of three times gross domestic product (GDP), Gardasil 4 vaccination for all women living with HIV aged 18-45 years was the most cost-effective strategy (ICER = US \32,766/QALY gained). This strategy would reduce genital warts by 35.52% (12,467/35,098), cervical cancers by 12.96% (46/355), and cervical cancer deaths by 12.39% (28/226) over the lifetime of the cohort. If the future domestic Cecolin 9 vaccine is priced at 60% of Gardasil 9, vaccinating all women living with HIV aged 18-45 years with Cecolin 9 would be the most cost-effective strategy (ICER = US \30,493/QALY gained). Improving adherence to antiretroviral therapy for HIV may substantially improve the cost-effectiveness of both Gardasil 4 and Cecolin 9 vaccination.
Item Description:Online verfügbar: 17. November 2024
Gesehen am 02.06.2025
Physical Description:Online Resource
ISSN:1097-0215
DOI:10.1002/ijc.35242

Similar Items